CelLBxHealth PLC (AIM:CLBX, FRA:DWV) CEO Peter Collins joined Proactive's Stephen Gunnion to discuss the company's strategic reset, progress with its Parsortix platform, and new collaborations with major healthcare and pharma players.
Collins described the first half of 2026 as "an absolute whirlwind," with the company overhauling its business, product portfolio and commercial strategy — focusing on improving circulating tumour cell (CTC) recovery and viability to support both internal programmes and external partners. New board appointments bring added commercial, diagnostics, healthcare and capital markets expertise, which Collins believes will help drive execution, particularly in the US.
On partnerships, Collins highlighted AstraZeneca's interest in CTC-based analysis to support its oncology pipeline, alongside a collaboration with AdventHealth using Parsortix in two large-scale cancer studies aimed at building clinical evidence for CTC-based patient monitoring.
Looking ahead, Collins pointed to growing recognition of CTCs' role in cancer biology and drug development: "CTCs are required to address critical questions that ctDNA and tissue are unable to do." He expects further partnering opportunities and progress toward clinical utility to support future growth.
For more videos featuring company executives and industry leaders, visit the Proactive YouTube channel. Don't forget to like this video, subscribe to the channel and enable notifications so you never miss future content.
#CelLBxHealth #PeterCollins #Parsortix #CancerResearch #Oncology #Biotech #Diagnostics #CirculatingTumorCells #CTC #AstraZeneca #AdventHealth #HealthcareInnovation #PrecisionMedicine #CancerDiagnostics #LifeSciences #Biopharma #ClinicalResearch #MedicalTechnology #Investing #AIMMarket
